Stock LIPO LIPELLA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Lipella Pharmaceuticals Inc.

Equities

LIPO

US53630L1008

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 10:12:52 2024-04-30 am EDT 		5-day change 1st Jan Change
0.723 USD -0.28% Intraday chart for Lipella Pharmaceuticals Inc. +0.80% -29.24%
Apr. 17 Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board CI
Apr. 09 Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target MT

Business Summary

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10, LP-310 and LP-410. LP-10 is the development name of its reformulation of tacrolimus specifically optimized for topical deposition to the internal surface of the urinary bladder lumen using a proprietary drug delivery platform. LP-310 is the development name of its oral, liposomal formulation of tacrolimus specifically optimized for local delivery to oral mucosa. It is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). LP-410 is an oral rinse, like LP-310, but has a different containment system. LP-410 targets the underlying mechanisms of oral GVHD, potentially providing a safe and effective treatment option for affected individuals.

Number of employees: 6

Sales per Business

USD in Million2022Weight2023Weight Delta
Biopharmaceuticals
100.0 %
0 100.0 % 0 100.0 % +144.15%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 0 100.0 % +144.15%

Managers

Managers TitleAgeSince
Michael Chancellor FOU
 Founder 67 04-12-31
Jonathan Kaufman CEO
 Chief Executive Officer 58 04-12-31
Douglas Johnston DFI
 Director of Finance/CFO 40 21-09-30
Janet Okonski CTO
 Chief Tech/Sci/R&D Officer - 21-07-31
Joseph Janicki CTO
 Chief Tech/Sci/R&D Officer - -
Michelle Gruber COO
 Chief Operating Officer - 08-12-31
Katie Johnston AUD
 Comptroller/Controller/Auditor - -
Allison Houck PRN
 Corporate Officer/Principal - -
Tomohiro Ueda PRN
 Corporate Officer/Principal - -
Robert Moldwin PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Jonathan Kaufman CEO
 Chief Executive Officer 58 04-12-31
Michael Chancellor FOU
 Founder 67 04-12-31
Byong Kim BRD
 Director/Board Member 54 22-02-28
Ryan Pruchnic BRD
 Director/Board Member 50 21-08-31
Naoki Yoshimura BRD
 Director/Board Member 67 21-08-31
Daniel Cohen BRD
 Director/Board Member 60 23-03-20
Lori Birder BRD
 Director/Board Member 64 23-06-16

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 6,750,034 3,674,759 ( 54.44 %) 0 54.44 %

Shareholders

NameEquities%Valuation
Jonathan Kaufman
14.22 %
888,849 14.22 % 608 862 $
Michael Chancellor
14.04 %
877,637 14.04 % 601 181 $
Leaf Huang
8.889 %
555,557 8.889 % 380 557 $
Richa Mishra
7.453 %
465,786 7.453 % 319 063 $
Spartan Capital Holdings LLC
6.400 %
400,000 6.400 % 274 000 $
Sabby Management LLC
4.317 %
269,829 4.317 % 184 833 $
Geode Capital Management LLC
0.6734 %
42,090 0.6734 % 28 832 $
Vanguard Group, Inc. (Subfiler)
0.5523 %
34,520 0.5523 % 23 646 $
Two Sigma Investments LP
0.2538 %
15,865 0.2538 % 10 868 $
Tower Research Capital LLC
0.1107 %
6,919 0.1107 % 4 740 $

Company contact information

Lipella Pharmaceuticals, Inc.

7800 Susquehanna Street Suite 505

15208, Pittsburgh

+412-901-0315

http://www.lipella.com
address Lipella Pharmaceuticals Inc.(LIPO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.725 USD
Average target price
2 USD
Spread / Average Target
+175.86%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LIPELLA PHARMACEUTICALS INC. Stock Lipella Pharmaceuticals Inc.
-28.92% 5.1M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.63% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.62% 96.29B
ARGENX SE Stock argenx SE
+2.01% 22.18B
BIONTECH SE Stock BioNTech SE
-16.67% 21.2B
GENMAB A/S Stock Genmab A/S
-9.33% 18.31B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 17.38B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.41% 13.97B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.57% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. LIPO Stock
  4. Company Lipella Pharmaceuticals Inc.